ArticleCureus2025
Docetaxel Rechallenge After Chemohormonal Therapy in High-Volume Metastatic Castration-Sensitive Prostate Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Docetaxel has been widely used in the treatment of both metastatic castration-resistant and castration-sensitive prostate cancers. However, limited evidence exists regarding the efficacy of docetaxel rechallenge (DR) in patients with metastatic castration-resistant prostate cancer (mCRPC) following prior chemohormonal therapy for high-volume metastatic castration-sensitive prostate cancer (mCSPC). This study aimed to evaluate clinical outcomes in such patients. Among 32 patients with high-volume mCSPC treated with chemohormonal therapy between 2020 and 2022, five underwent DR after progression to mCRPC. A retrospective review was performed to assess patient characteristics, changes in prostate-specific antigen (PSA) levels, and treatment-related adverse events. The median follow-up period was 26 months, and the median age at DR initiation was 74 years. The median time to progression to mCRPC was 27 months (range: 7-41 months). DR was administered as either first- or second-line therapy for mCRPC. Treatment was discontinued in two patients due to disease progression. A ≥50% decline in PSA levels was observed in two patients who received docetaxel as the first-line mCRPC therapy (40%). Grade 3 fatigue occurred in two patients, with low-grade alopecia being the most common adverse event. DR may provide limited clinical benefits in selected patients with mCRPC following prior chemohormonal therapy, particularly when treatment options are constrained. However, due to the small size and variability in response, the therapeutic role of the modality remains uncertain. Well-designed prospective studies with larger cohorts are needed to better define the clinical value of DR and establish evidence-based criteria for patient selection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.